Original article

Anxiety symptoms in crack cocaine and inhalant users admitted to a psychiatric hospital in southern Brazil

Carlos Zubaran a,b,*, Katia Foresti c,d, Mariana Rossi Thorell e, Paulo Roberto Franceschini e

a School of Medicine, University of Western Sydney, Sydney, Australia
b Department of Psychiatry, Blacktown Hospital, Sydney West Area Health Service, Sydney, Australia
c School of Medicine, Universidade de Caxias do Sul, Caxias do Sul, RS, Brazil
d Department of Psychiatry, Western Sydney Local Health District, Sydney, Australia
e Hospital Santa Casa de Misericórdia, Porto Alegre, RS, Brazil

ABSTRACT

Objective: The occurrence of psychiatric comorbidity among individuals with crack or inhalant dependence is frequently observed. The objective of this study was to investigate anxiety symptoms among crack cocaine and inhalant users in southern Brazil.

Methods: The study investigated two groups of volunteers of equal size (n = 50): one group consisted of crack cocaine users, and the other group consisted of inhalant users. Research volunteers completed the Portuguese versions of the State-Trait Anxiety Inventory (STAI), Hamilton Anxiety Rating Scale (HAM-A), and Self-Report Questionnaire (SRQ).

Results: Both crack and inhalant users experience significant symptoms of anxiety. Inhalant users presented significantly more anxiety symptoms than crack users according to the HAM-A questionnaire only. In contrast to the results of the HAM-A, the STAI failed to demonstrate a significant difference between the two groups of substance users. SRQ scores revealed that crack and inhalants users had significant degrees of morbidity.

Conclusion: A significant difference regarding anxiety symptomatology, especially state anxiety, was observed among inhalant and crack users. Anxiety and overall mental psychopathology were significantly correlated in this sample. The results indicate that screening initiatives to detect anxiety and additional psychiatric comorbidities among crack and inhalant users are feasible and relevant.

© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND

Sintomas de ansiedade em usuários de crack e inalantes admitidos em uma unidade psiquiátrica na Região Sul do Brasil

RESUMO

Objetivo: Investigar sintomas de ansiedade em usuários de crack e inalantes no Sul do Brasil.

Métodos: O estudo investigou dois grupos de voluntários com o mesmo número de indivíduos (n = 50): um grupo consistiu de usuários de crack e o outro grupo, de usuários de inalantes.
Introduction

Crack and inhalant abuse have been documented as two of the most common addictive disorders in Brazil.1,2 Crack cocaine and inhalants have been used in Brazil by street children,3 undergraduates,4 and medical students.5,6 Inhalants abuse and dependence negatively affect youth regardless of gender, ethnicity, age, and family income.7 The association between inhalant dependence and other psychiatric morbidities is higher than in patients with dependence to other psychoactive drugs, including alcohol.8

The co-occurrence of mood and anxiety disorders has been predominantly associated with adverse outcomes among young substance users.9 The prevalence figures of anxiety disorders among substance users vary according to different studies.10 In the Drug Abuse Treatment Outcome Study (DATOS), which assessed over 10,000 substance users, the prevalence of generalized anxiety disorder (GAD) ranged from 2.2% to 4.2%,11 while in studies with smaller sample sizes the prevalence rates of anxiety disorders varied substantially.12-14 Symptoms of anxiety were also the most common psychiatric manifestation among adolescents with substance use-related disorders (60% of both boys and girls).15 The significant association between any anxiety disorder and lifetime cocaine use has been consistently detected in an independent survey conducted in the US and Canada.16 In a Spanish cross-sectional study, nearly 42.5% of cocaine users recruited in non-clinical settings presented with a psychiatric comorbidity; anxiety disorders (13%) were the second most common comorbid disorder, after depression.17 Data from an international multicenter study revealed that the onset of anxiety disorders usually precedes the initiation of substance use disorders.18

The use of cocaine may precipitate panic attacks, phobia reactions, obsessions, and compulsions, which may persist after discontinuation of use.19,20 The comorbidity between cocaine use and social phobia21 and post-traumatic stress disorder (PTSD)22,23 tends to occur among individuals with severe cocaine use, with personal background and family history of psychiatric disorders.24 The association between anxiety disorder and cocaine use has been described in the context of affective disorder,25,26 and documented extensively among people with panic attacks.27-29 Treatment-seeking cocaine users also report significant levels of anxiety.14 Anxiety and mood disorders were the most common comorbid Axis I disorders diagnosed in a sample of male inpatients in Iowa.30 Anxiety is also a prominent clinical feature during the abstinence phase of cocaine withdrawal.31 In comparison with users of heroin only, users of both heroin and cocaine present significantly more symptoms of anxiety.32 Anxiety has also been considered as a risk factor for the occurrence of cocaine-induced paranoia.33

Anxiety disorders are commonly associated with inhalant use. The reported prevalence rate of generalized anxiety disorder among inhalant users is 20.5%.8 Data from a national epidemiological survey revealed that inhalant users had a significant lifetime prevalence of anxiety disorders (36%).34 Female inhalant users presented higher lifetime prevalence rates of any anxiety disorder in comparison with male users (53% versus 30%), including panic disorder without agoraphobia (25% versus 11%), and specific phobia (28% versus 14%). Female inhalant users also were more likely to have met the criteria for three or more anxiety disorders (15% versus 8%) in the past year.34 In addition, adolescents with inhalant abuse or dependence are significantly more likely to have abuse or dependence of alcohol, hallucinogens, nicotine, cocaine, and/or amphetamines, and are more likely to have attempted suicide compared with other adolescent patients who reported never using inhalants.35 Toluene is the main component of inhalants used by youth in Brazil, including homeless youth, as confirmed by urinary levels of hippuric acid.36,37

Considering the frequent occurrence of psychiatric comorbidity among individuals with crack or inhalant dependence, as well as the compounding and detrimental effects of this association, it is essential to carefully screen these drug users for anxiety.35,38 Furthermore, the majority of individuals affected by anxiety disorders have never obtained effective treatment despite the significant level of disability imposed by these conditions.39 The objective of this study was to investigate anxiety symptoms among crack cocaine and inhalant users in southern Brazil. To the authors’ knowledge, this is the first time that crack and inhalant users have been simultaneously assessed with two anxiety-specific measures in southern Brazil.

Methods

Sample

The study investigated two groups of volunteers of equal size (n = 50): one group consisted of crack cocaine users and the other group consisted of inhalant users. Both groups were...
interviewed as inpatient volunteers in wards of a tertiary care mental health facility and a higher education training site associated with the Universidade de Caxias do Sul. Drug users fulfilled the Diagnostic and Statistic Manual of Mental Disorders, 4th edition (DSM-IV) diagnostic criteria for crack cocaine or inhalant dependence, according to a psychiatric interview conducted upon admission by psychiatrists who were completely unfamiliar with this research protocol. Patients with polydrug dependence had to satisfy the inclusion criteria of using either crack cocaine or any type of inhalant drug as (a) the main addictive substance, and (b) the one causing the most salient dependence.

All patients who volunteered to participate in this investigation were assisted via the Brazilian public health system. Taking into account that a substantial fraction of the sample was illiterate or semi-illiterate, all drug users completed the questionnaires under minimal guidance by trained interviewers, who followed standardized instructional procedures. Uncompleted or inappropriately completed questionnaires were excluded from analysis. All volunteers spoke Portuguese as their first language.

**Informed consent and recruitment**

This study was endorsed by the institutional Ethics and Research Committees of the Universidade de Caxias do Sul (UCS), which regulate all scientific activities at UCS. All volunteers signed an informed consent. A certificate of confidentiality was guaranteed to all research participants. Consent from parents or legally responsible adults was obtained before minor participants were formally enrolled in the present study. All respondents were treated anonymously. Research participants were recruited via word-of-mouth. Drug users were approached to participate in this study after having achieved a stable clinical course, as determined by their own physician. The recruitment process took place during various consecutive months, according to the rate of hospital admissions of prospective participants. Research participants were interviewed only once for the purpose of this investigation.

**Research tools**

The State-Trait Anxiety Inventory (STAI) is one of the most widely used self-report measures of anxiety in clinical and research settings. The STAI measures two different components: state anxiety, which refers to a transitory and subjective emotional state that varies over time; and trait anxiety, which refers to a relatively stable pattern of reaction to stress with anxiety and a tendency to perceive situations as threatening. The Portuguese version of the STAI was validated in a sample of university students in Brazil. Each part varies from 20 to 80 points, and the scores indicate low (0–30), medium (31–49), or high (50 or more) anxiety levels.

The Hamilton Anxiety Rating Scale (HAM-A) was conceived as an easy-to-use instrument to measure state anxiety. The HAM-A has been used extensively to investigate symptoms of anxiety as well as the result of interventions aimed at reducing levels of anxiety. The Portuguese version of the HAM-A has been widely used for measuring mainly state anxiety. A score of 17 or below indicates absence of or low levels of anxiety; a score from 18 to 24 indicates low to moderate anxiety levels; while a score from 25 to 30 indicates moderate to severe anxiety levels.

The Self-Reporting Questionnaire (SRQ) was used to identify minor and general psychiatric morbidity. The SRQ was derived from research instruments used by the World Health Organization (WHO) for studying psychiatric morbidity in primary care settings in developing countries. According to SRQ, respondents were classified as high (≥ 8) or low (≤ 7) scorers.

The socio-economic status (SES) of research participants was assessed via a scale previously tested in Brazil. This instrument classifies SES into six categories: lower-lower, upper-lower, lower-middle, upper-middle, lower-upper, and upper-upper class.

**Statistical analyses**

Analysis of demographic variables was performed in relation to age and socioeconomic status. The overall scores of the HAM-A, STAI, and SRQ were computed and subsequently transformed into Z-scores for correlation and regression analyses. Student’s t-test for independent samples was performed to examine differences between two groups of drug users. Analyses of correlation via Pearson’s product-moment and Spearman’s rank coefficients were computed between the questionnaires’ scores and categories, respectively. Logistic regression analyses were also conducted to explore predictive effects of anxiety scales (HAM-A and STAI) on general psychopathology (SRQ). Statistical analyses were conducted using the Statistical Package for Social Sciences (SPSS®).

**Results**

**Demographic data**

The mean age in the overall sample was 20.2 years of age. The mean ages in the groups of crack users and inhalant users were 22.8 and 17.3 years of age, respectively. Regarding gender, the overall sample had 12% and 88% of female and male volunteers, respectively. Table 1 shows a summary of all demographic information.

Regarding SES, most of the total sample was classified as upper-lower class (30%) and lower-middle class (59%). A nonparametric analysis via Kruskal-Wallis test of the two subgroups differentiated according to SES strata revealed an absence of a significant difference in the medians between the two groups, with $\chi^2 (1, n = 100) = 2.15$, p = 0.142.

**Anxiety**

The mean scores of the both anxiety rating scales used in this study (HAM-A and STAI), in the combined sample of crack and inhalant users and in each separate group are shown in Table 2. According to the HAM-A classification, 71.7% of the sample did not have or had low levels of anxiety, while 28.3% presented anxiety. Considering each group separately, crack users and inhalants users presented the following results, respectively: 90% and 53.1% (absence or low
levels of anxiety, and 10% and 46.9% (presence of anxiety). Among crack users who experienced anxiety, 4% presented light to moderate levels of anxiety, while 6% presented moderate to severe levels of anxiety. Among inhalant users who experienced anxiety, 28.6% reported light to moderate levels of anxiety, while 18.4% presented moderate to severe levels of anxiety.

The STAI classified crack and inhalant users, in terms of presence or absence of anxiety, taken together, as follows: 9% (absence or low levels of anxiety) and 91% (presence of anxiety). The distribution according to the presence or absence of anxiety as classified by the STAI in the groups of crack and inhalant users, respectively, was as follows: 14% and 4% (absence or low levels of anxiety), and 86% and 96% (presence of anxiety). Among crack users who experienced anxiety, 72% presented medium levels of anxiety, while 14% presented high levels of anxiety. Among inhalant users who experienced anxiety, 78% reported medium levels of anxiety, while 18% presented high levels of anxiety.

A parametrical analysis using Student’s t-test for independent samples revealed a significant statistical difference between the two groups of drug users according to the scores of the HAM-A anxiety ratings scale: t(97) = -4.62, p < 0.001. A nonparametric analysis using the Mann-Whitney test of HAM-A scores according to a categorical distinction (absence or presence of anxiety, based on a cut-off point of > 17, as explained in the Methods section) also revealed a significant difference among the groups of crack and inhalant users, with z = -4.06, p < 0.001. This significant difference persisted when the three different categories of intensity were taken into account (z = -3.9, p < 0.001).

A parametrical analysis using Student’s t-test for independent samples revealed an absence of significant statistical difference between the two groups of drug users according to the STAI scores: t(98) = -1.54, p = 0.13. A nonparametric analysis using the Mann-Whitney test of STAI scores according to a categorical distinction (absence or presence of anxiety, based on a cut-off point of ≥ 31, as explained in the Methods section) also revealed an absence of significant difference between the groups of crack and inhalant users, with z = -1.74, p = 0.8. The absence of significant difference persisted when the different categories of intensity were analyzed (z = -1.37, p = 0.17).

**Correlation analyses**

Pearson product-moment correlation coefficients were computed among the overall scores of all questionnaires completed by the three groups. The Bonferroni method was used to control for type I error for all pair wise comparisons: $\alpha_{BC} = 0.05/3 = 0.17$.

A significant correlation was found between the scores of the HAM-A and the scores of the STAI in the combined sample of drug users ($r = 0.43$, $p < 0.001$). Spearman’s rank correlation analysis also revealed a significant association between the caseness (presence or absence of anxiety) generated by the HAM-A and the STAI ($r = 0.2$, $p < 0.05$).

Significant correlations were also found between the scores of HAM-A and SRQ ($r = 0.44$, $p < 0.001$) and between the scores of STAI and SRQ ($r = 0.67$, $p < 0.001$).

**Linear regression analyses**

Bivariate linear regression analyses were conducted, separately, to evaluate the prediction of general psychopathology scores (SRQ) according to the scores of the anxiety rating scales among crack and inhalant users.

---

**Table 1 – Sociodemographic characteristics of the total sample of substance users**

| Sociodemographic characteristics | Total (n = 100) | Crack (n = 50) | Inhalant (n = 50) |
|----------------------------------|----------------|---------------|------------------|
| Age                              |                |               |                  |
| Mean (± SD)                      | 20.1 (6.2)     | 22.8 (6.4)    | 17.3 (4.5)       |
| Range                            | 29 (11-40)     | 17 (11-28)    | 25 (15-40)       |
| Gender                           |                |               |                  |
| Male                             | 88             | 43 (86%)      | 45 (90%)         |
| Female                           | 12             | 7 (14%)       | 5 (10%)          |
| Socio-economic status            |                |               |                  |
| Lower-lower                      | 3              | 1 (2%)        | 2 (4%)           |
| Upper-lower                      | 32             | 15 (30%)      | 17 (34%)         |
| Lower-middle                     | 57             | 28 (56%)      | 29 (58%)         |
| Middle                           | 8              | 6 (12%)       | 2 (4%)           |

**Table 2 – Scores and case details of crack and inhalants users according to the HAM-A and the STAI questionnaires**

|                  | HAM-A (SD) | STAI (SD) |                  |
|------------------|------------|-----------|------------------|
|                  | Mean       | Absence/low levels of anxiety (%) | Presence of anxiety (%) | Mean       | Absence/low levels of anxiety (%) | Presence of anxiety (%) |
| Crack (n = 50)   | 8.38 (8.07) | 90        | 10               | 48.06 (10.52) | 14        | 86               |
| Inhalant (n = 50)| 16.45 (9.28) | 53.1     | 46.9              | 51 (8.39)     | 4         | 96               |
| Both groups      | 12.37 (9.54) | 71.7     | 28.3              | 49.53 (9.58)  | 9         | 91               |

HAM-A, Hamilton Anxiety Rating Scale; STAI, State-Trait Anxiety Inventory.
Discussion

The results presented in this study indicate that both crack and inhalant users experience significant symptoms of anxiety. The prevalence of anxiety among crack users varies from 10% (HAM-A) to 86% (STAI), while among inhalant users the figures vary from 46.9% (HAM-A) to 96% (STAI). Crack users presented significantly more anxiety symptoms than inhalant users according to the HAM-A questionnaire only. This difference was observed when results were treated parametrically and non-parametrically. These findings are consistent with results obtained by other studies, which revealed that anxiety is, among other psychiatric symptoms, a frequent comorbidity among crack cocaine users.17 Crack cocaine users, in particular, are known to present with significant psychiatric comorbidities, including depression, anxiety disorders, bipolar disorder, and attention-deficit/hyperactivity disorder, with eventual fatal outcomes.52,53 In Brazil, treatment-seeking non-intravenous cocaine users presented a lifetime prevalence of Axis I or Axis II disorders of 69%, and anxiety disorders were the most common psychiatric disorder (31%).54 The higher prevalence of anxiety disorders among cocaine dependent subjects encompasses different dysfunctions such as general anxiety, phobic, panic, and obsessive-compulsive disorders.55 Although the physiological and psychoactive effects of cocaine are similar regardless of its hydrochloride or crack form, evidence indicates a greater abuse liability and propensity for dependence, as well as more severe consequences, when cocaine is smoked or injected intravenously in comparison with intranasal use.56 In Brazil, a significant tendency to change routes of administration and patterns of cocaine use has been documented by several studies in the last decade.1,44,57–60

Contrarily to the results of the HAM-A, the STAI failed to demonstrate a significant difference between the two groups of substance users. There are conceptual differences between the two scales used to evaluate anxiety in this sample. The HAM-A measures state anxiety, which is a symptomatic expression, while the STAI also captures trait anxiety, which is related to characteriological issues.45 The differences between “state” and “trait” anxiety reflect the conceptual distinction between existing anxiety as a transitory state and the anxiety as a relatively stable personality characteristic.61,62 STAI scores may suffer from being influenced by different illness variables, such as severity, chronicity, and comorbidity of symptoms.63 Although variations in ratings have been reported with the HAM-A as well,64,65 the STAI was unable to distinguish between anxiety and depression in a mixed group of patients with both conditions, from which the authors concluded that the STAI does have clinical utility for measuring emotional distress.53 In the present study, only the trait subset of the STAI was used. The results of this study suggest therefore that trait anxiety is not significantly affected by crack and inhalant use, and that only measures of state anxiety should be used for the assessment of anxiety related to cocaine and inhalant use.

Considering the contrasting results produced by different scales used to measure anxiety, there is an increased need to investigate possible differences in the symptomatic...
measurement among patients with anxiety. Although psychometric measures have been produced extensively in psychiatry, sometimes via a single assessment tool, it has been advocated that anxiety and depression may be similar elements of a general psychological distress experience of difficult differentiation. Likewise, depression is a disorder with important clinical significance among crack cocaine users. A previous study detected a lifetime prevalence of 17.8% for depression among crack cocaine users. Prevalence of depression among crack users is believed to be higher than what has been previously reported. Furthermore, studies that investigated depressive disorders among crack users have detected additional psychiatric comorbidities, including anxiety, bipolar disorder, and attention-deficit/hyperactivity disorder, with eventual fatal outcomes.

Regarding psychiatric morbidity, the scores generated by the SRQ revealed that crack and inhalants users had significant degrees of morbidity. The SRQ has been previously used as a general screening tool for mental disorders in the context of substance abuse. Furthermore, in a community-based study conducted in southern Brazil, in which 126 adolescents were screened for mental problems, the prevalence of depressive symptoms, suicidal ideation, and hopelessness were higher among those who were detected as SRQ-positive according to a cut-off score of ≥ 8, the same threshold used in the present study.

The results of Pearson correlation analyses also revealed a significant correlation among anxiety symptoms and general psychopathology, which attest to a congruent measurement of the constructs investigated in this study. Furthermore, the results of the bivariate linear regression analyses also revealed that the scores of the two anxiety rating scales used in this study can predict, with significant accuracy, the scores of general psychopathology of crack and inhalant users.

Previous evidence, based on regression analyses of data from a national survey in the United States, revealed that inhalant users had greater odds of intravenous drug use than users who had not used inhalants. The results presented here reveal a direct and predictive association between depressive symptoms and general mental disorder among crack and inhalant users. Although additional studies are required to further substantiate these findings, these results may recommend more rigorous and extensive screening efforts to detect and treat depressive symptoms among crack and inhalant users.

This study may present some limitations, especially in relation to the nature of the sample investigated. Some of these discrepancies were revealed in the analyses of demographic data. Firstly, regarding age range, inhalant users presented a lower mean age in comparison with crack users. The reasons for the early age of inhalant use are based on the fact that many organic solvents are present in wide array of chemical compounds publicly commercialized for a broad variety of household purposes, which facilitate children’s access. In fact, inhalant use has been characterized as preferentially prevalent among children and juveniles in both developed and developing economies. In Brazil, as well as in other developing countries, inhalants tend to be the preferred drug used among the street children, who are who live and wander unsupervised on the streets of major urban centers.

Secondly, male participants predominated significantly in both groups. Evidence based on a series of surveys conducted with Brazilian secondary school students demonstrated an increased use of illicit psychotropic drugs by males, while women prefer to use drugs in the form of pills, such as anxiolytics and amphetamines.

Thirdly, the psychometric tools used in this study were not specifically designed to evaluate adolescents. Although the mean age in the overall sample was 20.1 years, the mean age of inhalant users was 17.3 years. Nevertheless, most of the instruments used in this study have been tested previously as screening tools among adolescents in southern Brazil. Furthermore, the unavailability of versions validated in Portuguese of instruments developed specifically for assessing adolescents’ mental health prevented, at this stage, the use of a more suitable methodology for this sample. This limitation highlights the need for validation studies of psychometric instruments among adolescents in Brazil.

Despite the above-mentioned limitations, the sample investigated in this study was recruited in public health facilities, where members of all socio-economic strata of the Brazilian society have prompt access to health care. This advantage is particularly relevant in the case of a study conducted in a developing economy, where inequalities of care are known to produce significant health differentials.

Conclusion

A significant difference regarding anxiety symptomatology, especially state anxiety, was observed among inhalant and crack users. Anxiety and overall mental psychopathology were significantly correlated in this sample. The results indicate that screening initiatives to detect anxiety and additional psychiatric comorbidities among crack and inhalant users are feasible and relevant. Considering that drug abuse, especially of inhalants, affect youth preferentially, and that adolescence is a vulnerable life cycle phase, the present findings justify more rigorous and extensive screening efforts to detect and treat anxiety disorders among crack cocaine and inhalant users.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

The authors acknowledge the contribution of several students in the research group during the initial phases of this investigation.

This study was partially supported by grant No. 000605-25.00/03-8 from the Science and Technology State Agency, Rio Grande do Sul, Brazil.
REFERENCES

1. Dunn J, Laranjeira RR, da Silveira DX, Formigoni ML, Ferri CP. Crack cocaine: an increase in use among patients attending clinics in São Paulo: 1990-1993. Substance Use Misuse. 1996;31:519–27.

2. Galduróz JC, Noto AR, Nappo SA, Carlini EL. First household survey on drug abuse in São Paulo, Brazil, 1999: principal findings. São Paulo Med J. 2003;121:231–7.

3. Noto AR, Nappo SA, Galduróz JC, Mattei R, Carlini EA. Use of drugs among street children in Brazil. J Psychoactive Drugs. 1997;29:185–92.

4. Stemplerk Vde A, Barroso LP, Andrade AG, Nicastrri S, Malbergier A. Comparative study of drug use among undergraduate students at the University of São Paulo – São Paulo campus in 1996 and 2001. Rev Bras Psiquiatr. 2005;27:185–93.

5. Boniatti MM, Zubaran C, Paramarotto D, Delazeri GJ, Tirello JL, Feldens MO, et al. The use of psychoactive substances among medical students in southern Brazil. Drug Alcohol Rev. 2007;26:279–85.

6. Mesquita AM, de Andrade AG, Anthony JC. Use of the inhalant lançã by Brazilian medical students. Subst Use Misuse. 1998;33:1667–80.

7. Wu LT, Pilowsky DJ, Schlenge WE. Inhalant abuse and dependence among adolescents in the United States. J Am Acad Child Adolesc Psychiatry. 2004;43:1206–14.

8. Evren C, Barut T, Saatcioglu O, Cakmak D. Axis I psychiatric comorbidity among adult inhalant dependent seeking treatment. J Psychoactive Drugs. 2006;38:57–64.

9. Lubman DJ, Allen NB, Rogers N, Clementon E, Bonomo Y. The impact of co-occurring mood and anxiety disorders among substance-abusing youth. J Affect Disord. 2007;103:105–12.

10. Ochoa Mangado E. Cocaine and psychiatric comorbidity. Actas Esp Psiquiatr. 2000;28:49–52.

11. Tims F, editor. The Drug Abuse Treatment Outcome Study (DATOS): a national multisite study of treatment effectiveness. Nordwijkherout, The Netherlands: International Conference on Treatment of Addictive Behaviors; 1995.

12. Brady KT, Grice DE, Dustan L, Randall C. Gender differences in substance use disorders. Am J Psychiatry. 1993;150:1707–11.

13. Kleiman PH, Miller AB, Millman RB, Woody GE, Todd T, Kemp J, et al. Psychopathology among cocaine abusers entering treatment. J Nerv Ment Dis. 1990;178:442–7.

14. Bounaisvile BJ, Anton SF, Carroll K, Budde D, Prusoff BA, Gwain F. Psychiatric diagnoses of treatment-seeking cocaine abusers. Arch Gen Psychiatry. 1991;48:43–51.

15. Shrier LA, Harris SK, Kurland M, Knight JR. Substance use problems and associated psychiatric symptoms among adolescents in early care. Pediatrics. 2003;111:e699–705.

16. Sareen J, Chartier M, Paulus MP, Stein MB. Illicit drug use and anxiety disorders: findings from two community surveys. Psychiatry Res. 2006;142:11–7.

17. Herrero MJ, Domingo-Salvany A, Torrens M, Brugal MT. Psychiatric comorbidity in young cocaine users: induced versus independent disorders. Addiction. 2008;103:284–93.

18. Merikangas KR, Mehta RL, Molnar BE, Walters EE, Swendsen JD, Aguilar-Gaxiola S, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav. 1998;23:893–907.

19. Anthony JC, Tien AT, Petronis KR. Epidemiologic evidence on cocaine use and panic attacks. Am J Epidemiol. 1989;129:543–9.

20. Rosenbaum JF. Cocaine and panic disorder. Am J Psychiatry. 1986;143:1320.

21. Myrick H, Brady KT. Social phobia in cocaine-dependent individuals. Am J Addict. 1997;6:99–104.

22. Cottler LB, Compton WM, Mager D, Spitznagel EL, Janca A. Posttraumatic stress disorder among substance users from the general population. Am J Psychiatry. 1992:149:664–70.

23. McFall ME, Mackay PW, Donovan DM. Combat-related posttraumatic stress disorder and severity of substance use in Vietnam veterans. J Stud Alcohol. 1992;53:357–63.

24. Satel SI, McDougle CJ. Obsessions and compulsions associated with cocaine abuse. Am J Psychiatry. 1991;148:947.

25. Goodwin RD, Stayner DA, Chinman MJ, Wu P, Tebes JK, Davidson L. The relationship between anxiety and substance use disorders among individuals with severe affective disorders. Compr Psychiatry. 2002;43:245–52.

26. Kolodziej ME, Griffen ML, Najavits LM, Otto MW, Greenfield SF, Weiss RD. Anxiety disorders among patients with co-occurring bipolar and substance use disorders. Drug Alcohol Depend. 2005;80:251–7.

27. Cox BJ, Norton GR, Swinson RP, Endler NS. Substance abuse and panic-related anxiety: a critical review. Behav Res Ther. 1990;28:385–93.

28. Valenti DP, Mounts NS, Deacon BJ. Panic attacks, depression and anxiety symptoms, and substance use behaviors during late adolescence. J Anxiety Disord. 2004;18:573–85.

29. Deacon BJ, Valenti DP. Substance use and non-clinical panic attacks in a young adult sample. J Subst Abuse. 2000;117–15.

30. Skinstad AH, Swain A. Comorbidity in a clinical sample of substance abusers. Am J Drug Alcohol Abuse. 2001;27:45–64.

31. Wood DM, Lal H. Anxiogenic properties of cocaine withdrawal. Life Sci. 1987;41:1431–6.

32. Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD. Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. Am J Drug Alcohol Abuse. 1986;12:1–16.

33. Rosse RB, Alim TN, Johri SK, Hess AL, Deutsch SL. Anxiety and pupil reactivity in cocaine dependent subjects endorsing cocaine-induced paranoia: preliminary report. Addiction. 1995;90:981–4.

34. Wu LT, Howard MO. Psychiatric disorders in inhalant users: results from The National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 2007;88:146–55.

35. Sakai JT, Hall SK, Mikulich-Gibertson SK, Crowley TJ. Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems. J Am Acad Child Adolesc Psychiatry. 2004;43:1080–8.

36. Thiesen FV, Barros HM. Measuring inhalant abuse among homeless youth in southern Brazil. J Psychoactive Drugs. 2004;36:201–5.

37. Thiesen FV, Noto AR, Barros HM. Laboratory diagnosis of tolual-based inhalant abuse. Clin Toxicol (Phila). 2007;45:557–62.

38. Torrens M, Martin-Santos R, Samet S. Importance of clinical diagnoses for comorbidity studies in substance use disorders. NeuroTox Res. 2006;10:253–61.

39. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64:566–76.

40. Keedwell P, Snaith RP. What do anxiety scales measure? Acta Psychiatr Scand. 1996;93:177–80.

41. Spielberger CD, Gorsuch RL, Lushene RE. Manual for the Trait-State Anxiety Inventory (“self-evaluation questionnaire”). Palo Alto: Consulting Psychologists Press; 1970.
42. Gorenstein C, Andrade L. Validation of a Portuguese version of the Beck Depression Inventory and the State-Trait Anxiety Inventory in Brazilian subjects. Braz J Med Biol Res. 1996;29:453–7.

43. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5.

44. Ferreira L, Figueira ML, Bessa-Peixoto A, Mareheiro A, Albuquerque R, Paz C, et al. Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder. Clin Drug Investig. 2003;23:235–43.

45. Sougey E. As escalas de avaliação nos ensaios clínicos com benzodiazepínicos: a propósito da escala de ansiedade de Hamilton. J Bras Psiquiatr. 1987;36:49–53.

46. Almeida C, Brasil MA, Costa AJ, Reis FA, Reuters V, Teixeira P, et al. Subclinical hypothyroidism: psychiatric disorders and symptoms. Rev Bras Psiquiatr. 2007;29:157–9.

47. Iacoponi E, Mari JI. Reliability and factor structure of the Portuguese version of Self-Reporting Questionnaire. Int J Soc Psychiatry. 1989;35:213–22.

48. Harding TW, Climent CE, Diop M, Giel R, Ibrahim HH, Murthy RS, et al. The WHO collaborative study on strategies for extending mental health care, II: the development of new research methods. Am J Psychiatry. 1983;140:1474–80.

49. Harding TW, de Arango MV, Baltazar J, Climent CE, Ibrahim HH, Ladrigo-Ignacio L, et al. Mental disorders in primary health care: a study of their frequency and diagnosis in four developing countries. Psychol Med. 1980;10:231–41.

50. Mari JI, Williams P. A validity study of a psychiatric screening questionnaire (SRQ-20) in primary care in the city of Sao Paulo. Br J Psychiatry. 1986;148:23–6.

51. Lombardi C, Bronfman M, Facchini IA, Victora CG, Barros FC, Béria JU, et al. Operacionalização do conceito de classe social em estudos epidemiológicos. Rev Saúde Publica. 1988;22:253–65.

52. Almeida C, Brasil MA, Costa AJ, Reis FA, Reuters V, Teixeira P, et al. Subclinical hypothyroidism: psychiatric disorders and symptoms. Rev Bras Psiquiatr. 2007;29:157–9.

53. Deas D. Adolescent substance abuse and psychiatric comorbidities. J Clin Psychiatry. 2006;67 Suppl 7:18–23.

54. Razzouk D, Bordin IA, Jorge MR. Comorbidity and global functioning (DSM-III-R Axis V) in a Brazilian sample of cocaine users. Subst Use Misuse. 2000;35:1307–15.

55. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511–8.

56. Hatsu Kam DI, Fishman MW. Crack cocaine and cocaine hydrochloride. Are the differences myth or reality? JAMA. 1996;276:1580–8.

57. Ferri CP, Gossop M. Route of cocaine administration: patterns of use and problems among a Brazilian sample. Addict Behav. 1999;24:815–21.

58. Ferri CP, Gossop M, Laranjeira RR. High dose cocaine use in Sao Paulo: a comparison of treatment and community samples. Subst Use Misuse. 2001;36:237–55.

59. Ferri CP, Dunn J, Gossop M, Laranjeira R. Factors associated with adverse reactions to cocaine among a sample of long-term, high-dose users in Sao Paulo, Brazil. Addict Behav. 2004;29:365–74.

60. Dunn J, Laranjeira RR. Transitions in the route of cocaine administration–characteristics, direction and associated variables. Addiction. 1999;94:813–24.

61. Addolorato G, Ancona C, Capristo E, Graziosetto R, Di Rienzo L, Maurizi M, et al. State and trait anxiety in women affected by allergic and vasomotor rhinitis. J Psychosom Res. 1999;46:283–9.

62. Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol. 1997;32:1013–21.

63. Kennedy BL, Schwab JJ, Morris RI, Beldia G. Assessment of state and trait anxiety in subjects with anxiety and depressive disorders. Psychiatr Q. 2001;72:263–76.

64. Robinson JK, Boshier ML, Dansak DA, Peterson KJ. Depression and anxiety in cancer patients: evidence for different causes. J Psychosom Res. 1985;29:133–8.

65. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phelenezil vs. atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry. 1992;49:290–300.

66. Endler NS, Cox BJ, Parker JD, Bagby RM. Self-reports of depression and state-trait anxiety: evidence for differential assessment. J Pers Soc Psychol. 1992;63:832–8.

67. Falck RS, Wang J, Carlson RG, Eddy M, Siegal HA. The prevalence and correlates of depressive symptomatology among a community sample of crack-cocaine smokers. J Psychoactive Drugs. 2002;34:281–8.

68. Falck RS, Wang J, Siegal HA, Carlson RG. The prevalence of psychiatric disorder among a community sample of crack cocaine users: an exploratory study with practical implications. J Nerv Ment Dis. 2004;192:503–7.

69. Schlesinger CM, Ober C, McCarthy MM, Watson JD, Seinen A. The development and validation of the Indigenous Risk Impact Screen (IRIS): a 13-item screening instrument for alcohol and drug and mental health risk. Drug Alcohol Rev. 2007;26:109–17.

70. Fidalgo TM, da Silveira ED, da Silveira DX. Psychiatric comorbidity related to alcohol use among adolescents. Am J Drug Alcohol Abuse. 2008;34:83–9.

71. de Carvalho SV, Collakis ST, de Oliveira MP, da Silveira DX. Frequency of pathological gambling among substance abusers under treatment. Rev Saúde Pública. 2005;39:717–22.

72. Goncalves DM, Stein AT, Kapczinski F. Performance of the Self-Reporting Questionnaire as a psychiatric screening questionnaire: a comparative study with Structured Clinical Interview for DSM-IV-TR. Cad Saúde Pública. 2008;24:380–90.

73. Feijo RB, Saveressig M, Salazar C, Chaves MLF. Menthal health screening by self-report questionnaire among community adolescents in Southern Brazil. J Adolesc Health. 1997;20:232–7.

74. Frank B, Marel R, Schmeidler J. The continuing problem of youthful solvent abuse in New York State. NIDA Res Monogr. 1988;85:77–105.

75. Lavik NJ. Drug abuse among junior high school students in Norway. Pediatrician. 1987;14:45–50.

76. Cooke BR, Evans DA, Farrow SC. Solvent misuse in secondary school children - a prevalence study. Community Med. 1988;10:8–13.

77. Duque LF, Rodriguez E, Huertas J. Use of inhalants in Colombia. NIDA Res Monogr. 1995;148:79–99.

78. Medina-Mora ME, Berenzon S. Epidemiology of inhalant abuse in Mexico. NIDA Res Monogr. 1995;148:136–74.

79. Baldivieso LE. Inhalant abuse in Bolivia. NIDA Res Monogr. 1995;148:50–63.

80. Forster LM, Tannhauser M, Barros HM. Drug use among street children in southern Brazil. Drug Alcohol Depend. 1996;43:57–62.